Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard S&P 500 ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Vanguard S&P 500 ETF trades at $713.81 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 132158.6× Citius Pharmaceuticals Inc's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Vanguard S&P 500 ETF for 55 Days on average.
| CTXR | VOO | |
|---|---|---|
Market Cap | $13.62M | $1.80T |
Volume | 132,438 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $716.17 |
52-Week Low | $0.48 | $580.93 |
Typical Hold Time | 16 Days | 55 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
VOO trades at $714.42, down 0.24% with a mild bearish daily move. Technical indicators show a bullish moving average signal but neutral oscillators, with RSI at 75.83 suggesting potential overbought conditions. Recent news highlights the ETF's role in long-term wealth building amid expectations of slowing S&P 500 profit growth from 35% to 15% in 2027. Short interest increased 46.9% in September, indicating growing bearish bets.
The outlook remains cautiously optimistic given VOO's diversified exposure to the S&P 500, though elevated RSI and rising short interest signal near-term pressure. Key risks include macroeconomic headwinds from Fed rate hikes and projected earnings slowdown. The ETF continues to be favored for recession resilience and long-term dollar-cost averaging strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
